Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research
- PMID: 23607746
- PMCID: PMC3809391
- DOI: 10.1089/aid.2013.0032
Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research
Abstract
Topical vaginal microbicides have been considered a promising option for preventing the male-to-female sexual transmission of HIV; however, clinical trials to date have not clearly demonstrated robust and reproducible effectiveness results. While multiple approaches may help enhance product effectiveness observed in clinical trials, increasing the drug exposure in lower genital tract tissues is a compelling option, given the difficulty in achieving sufficient drug exposure and positive correlation between tissue exposure and microbicide efficacy. Since many microbicide drug candidates are substrates of transporters and/or metabolizing enzymes, there is emerging interest in improving microbicide exposure and efficacy through local modulation of transporters and enzymes in the female lower genital tract. However, no systematic information on transporter/enzyme expression is available for ectocervical and vaginal tissues of premenopausal women, the genital sites most relevant to microbicide drug delivery. The current study utilized reverse transcriptase polymerase chain reaction (RT-PCR) to examine the mRNA expression profile of 22 transporters and 19 metabolizing enzymes in premenopausal normal human ectocervix and vagina. Efflux and uptake transporters important for antiretroviral drugs, such as P-gp, BCRP, OCT2, and ENT1, were found to be moderately or highly expressed in the lower genital tract as compared to liver. Among the metabolizing enzymes examined, most CYP isoforms were not detected while a number of UGTs such as UGT1A1 were highly expressed. Moderate to high expression of select transporters and enzymes was also observed in mouse cervix and vagina. The implications of this information on microbicide research is also discussed, including microbicide pharmacokinetics, the utilization of the mouse model in microbicide screening, as well as the in vivo functional studies of cervicovaginal transporters and enzymes.
Similar articles
-
Expression and localization of p-glycoprotein, multidrug resistance protein 4, and breast cancer resistance protein in the female lower genital tract of human and pigtailed macaque.AIDS Res Hum Retroviruses. 2014 Nov;30(11):1106-16. doi: 10.1089/AID.2013.0281. Epub 2014 Jun 12. AIDS Res Hum Retroviruses. 2014. PMID: 24803409 Free PMC article.
-
Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits.Mol Pharm. 2014 Dec 1;11(12):4405-14. doi: 10.1021/mp5005004. Epub 2014 Nov 4. Mol Pharm. 2014. PMID: 25327902
-
In Vivo Modulation of Cervicovaginal Drug Transporters and Tissue Distribution by Film-Released Tenofovir and Darunavir for Topical Prevention of HIV-1.Mol Pharm. 2020 Mar 2;17(3):852-864. doi: 10.1021/acs.molpharmaceut.9b01121. Epub 2020 Feb 20. Mol Pharm. 2020. PMID: 32017579
-
Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.J Control Release. 2015 Dec 10;219:681-696. doi: 10.1016/j.jconrel.2015.08.018. Epub 2015 Aug 13. J Control Release. 2015. PMID: 26278511 Free PMC article. Review.
-
Clinical development of microbicides for the prevention of HIV infection.Curr Pharm Des. 2004;10(3):315-36. doi: 10.2174/1381612043386374. Curr Pharm Des. 2004. PMID: 14754390 Review.
Cited by
-
Transport and Permeation Properties of Dapivirine: Understanding Potential Drug-Drug Interactions.Pharmaceutics. 2022 Sep 14;14(9):1948. doi: 10.3390/pharmaceutics14091948. Pharmaceutics. 2022. PMID: 36145696 Free PMC article.
-
Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.Clin Pharmacokinet. 2014 Jul;53(7):611-24. doi: 10.1007/s40262-014-0148-z. Clin Pharmacokinet. 2014. PMID: 24859035 Free PMC article. Review.
-
Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel.J Acquir Immune Defic Syndr. 2018 May 1;78(1):82-92. doi: 10.1097/QAI.0000000000001648. J Acquir Immune Defic Syndr. 2018. PMID: 29424790 Free PMC article.
-
Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics.Am J Reprod Immunol. 2014 Jun;71(6):523-30. doi: 10.1111/aji.12210. Epub 2014 Feb 13. Am J Reprod Immunol. 2014. PMID: 24521428 Free PMC article. Review.
-
Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions.Anaerobe. 2017 Jun;45:10-18. doi: 10.1016/j.anaerobe.2017.04.014. Epub 2017 Apr 26. Anaerobe. 2017. PMID: 28456518 Free PMC article.
References
-
- Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature. 2010;464(7286):217–223. - PubMed
-
- Kis O. Robillard K. Chan GN. Bendayan R. The complexities of antiretroviral drug-drug interactions: Role of ABC and SLC transporters. Trends Pharmacol Sci. 2010;31(1):22–35. - PubMed
-
- Hendrix CMA. Guddera V, et al. MTN-001: A Phase 2 Cross-over Study of Daily Oral and Vaginal TFV in Healthy, Sexually Active Women Results in Significantly Different Product Acceptability and Vaginal Tissue Drug Concentrations. Paper presented at the 18th Conference on Retroviruses and Opportunistic Infections; 2011.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous